drugset / Trial / NCT04386746
Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer
Phase 2
Active not recruiting
27 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NaSingle-groupOpen-labelTreatment
Summary
A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-naïve patients with non-muscle invasive bladder cancer (NMIBC).
Timeline
- Start
- 2020-07-29
- Primary completion
- 2022-10-04
- Completion
- 2026-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 37.5 mg | Other |
| Subject | Gemcitabine | Small molecule | 1000 mg | Other |